Works matching IS 23752130 AND DT 2024 AND VI 10 AND IP 1
Results: 14
Up to 67% of Patients Achieve MASH Resolution at 36 Weeks With Efruxifermin.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 21
- By:
- Publication type:
- Article
Low-Dose Aspirin ‘Potential Therapeutic Option’ for MASLD, Markedly Reduces Steatosis.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 20
- Publication type:
- Article
VIDEO: Flexible Parental Leave Policies Increase Inclusivity, Reduce Burnout in GI.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 18
- Publication type:
- Article
AGA Recommends Use of Fecal Calprotectin, Serum CRP to Inform Crohn’s Disease Management.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 17
- Publication type:
- Article
FDA Grants Fast Track Status to Monoclonal Antibody for Primary Sclerosing Cholangitis.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 10
- Publication type:
- Article
GI Psychologists Help Navigate ‘Complexities’ of Various GI Conditions, Personalize Care.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 42
- By:
- Publication type:
- Article
On-Demand Vonoprazan May Replace Daily Therapy for Nonerosive Reflux Disease.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 41
- Publication type:
- Article
‘Small Difference’ in Colorectal Neoplasia Recurrence at 5 vs. 10 Years After Polypectomy.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 40
- Publication type:
- Article
Triple Combination Therapy ‘Superior to Monotherapy,’ Improves Remission in Crohn’s.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 38
- Publication type:
- Article
‘We Must Act’: Physician Burnout Reaches ‘Crisis Levels’ in COVID-19 Aftermath.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 32
- By:
- Publication type:
- Article
Pegozafermin Improves Stage 4 Fibrosis, Noninvasive Markers in MASH Patients.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 30
- By:
- Publication type:
- Article
Aldafermin 3 mg Signifi cantly Reduced Enhanced Liver Fibrosis Score in MASH.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 29
- Publication type:
- Article
Joint Statement Calls for FDA to Require Drug Trials to Include People With Obesity.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 8
- Publication type:
- Article
ENLIVEN Extension Topline Data: Pegozafermin Sustains ‘Robust Benefits’ in NASH at Week 48.
- Published in:
- Healio Gastroenterology, 2024, v. 10, n. 1, p. 7
- By:
- Publication type:
- Article